131 Dartmouth Street
3rd Floor
Boston, MA 02116
United States
650 503 9095
https://www.adicetbio.com
Settore/i:
Settore:
Impiegati a tempo pieno: 143
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Mr. Chen Schor BA, CPA, M.B.A. | CEO, President & Director | 899,58k | N/D | 1972 |
Dr. Aya Jakobovits Ph.D. | Founder & Independent Director | 40k | N/D | 1956 |
Dr. Blake Aftab Ph.D. | Senior VP & Chief Scientific Officer | 675,04k | N/D | 1981 |
Dr. Francesco Galimi M.D., Ph.D. | Chief Medical Officer & Senior VP | 680,37k | N/D | 1968 |
Mr. Brian Nicholas Harvey | Chief Financial Officer | 596,79k | N/D | 1961 |
Dr. Donald Healey Ph.D. | Chief Technology Officer | N/D | N/D | 1962 |
Ms. Amy Locke | Chief Human Resource Officer | N/D | N/D | N/D |
Dr. Nancy L. Boman M.D., Ph.D. | Senior VP & Chief Regulatory Officer | N/D | N/D | N/D |
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. The company is also developing ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma for treating other CD70+ solid tumor and hematological malignancies indications. The company was founded in 2014 and is based in Boston, Massachusetts.
L'ISS Governance QualityScore di Adicet Bio, Inc. al 1 aprile 2024 è 9. I criteri di valutazione fondamentali sono revisione: 6; Consiglio di Amministrazione: 9; diritti degli azionisti: 8; retribuzione: 9.